Royalty Pharma PLC 8-K filings

Royalty Pharma plc reported robust second quarter 2026 financial results, with significant growth in Royalty Receipts and an increase in Portfolio Receipts, leading to an upward revision of full-year 2026 guidance.

Royalty Pharma plc shareholders voted on 10 proposals at the 2026 Annual General Meeting, including director elections and compensation approvals.

Royalty Pharma plc has entered into a new $1.8 billion unsecured revolving credit agreement, refinancing its existing 2021 facility.

Royalty Pharma plc announced robust first-quarter 2026 financial results, with double-digit growth in Royalty and Portfolio Receipts, and raised its full-year 2026 guidance.

Royalty Pharma plc announced an additional $250 million funding to Revolution Medicines following positive Phase 3 trial results for daraxonrasib in pancreatic cancer.

Royalty Pharma announced robust financial results for Q4 and full year 2025, driven by double-digit portfolio growth and strategic capital deployment, alongside optimistic 2026 guidance.

Royalty Pharma plc announced the planned transition of its Executive Vice President and Chief Legal Officer, George W. Lloyd, effective December 31, 2025.

Royalty Pharma's investment in Cytokinetics' MYQORZO is set to generate significant royalties and repayments following FDA approval for obstructive hypertrophic cardiomyopathy.

Royalty Pharma reported strong third quarter 2025 financial results, with double-digit growth in Portfolio Receipts and Royalty Receipts, and raised its full year 2025 guidance.

Royalty Pharma plc successfully closed a $2 billion offering of senior unsecured notes with maturities in 2031, 2035, and 2055.

Henry Fernandez has stepped down from Royalty Pharma's Board of Directors and as Lead Independent Director, effective August 13, 2025.

Royalty Pharma reported robust second quarter 2025 results with 20% Portfolio Receipts growth and raised full-year guidance, alongside strategic acquisitions and new funding agreements.

Royalty Pharma plc has strengthened its Board of Directors with the appointment of two highly experienced independent members, increasing independent representation to over 90%.

Royalty Pharma plc subsidiary finalizes acquisition of RP LLC, amends loan agreement, and restates exchange agreement to accommodate new shareholders and share classes.

Royalty Pharma plc held its 2025 Annual General Meeting and Special Meeting of Shareholders on May 12, 2025, where shareholders voted on and approved 15 proposals.

Royalty Pharma announced a 17% increase in Portfolio Receipts to $839 million for Q1 2025 and raised its full-year guidance.

Royalty Pharma plc amends its purchase agreement with Royalty Pharma Manager, LLC to include a share subscription component, allowing sellers to subscribe for Class B ordinary shares of Royalty Pharma.

Royalty Pharma plc appoints Vlad Coric, M.D., Chairman and CEO of Biohaven, to its Board of Directors, effective immediately.

Royalty Pharma announces strong 2024 results with double-digit growth in Royalty Receipts, driven by key products, and outlines 2025 guidance, alongside strategic moves including acquiring its external manager and initiating a $3 billion share repurchase.

Royalty Pharma is set to acquire its external manager, RP Management, and has announced a new $3 billion share repurchase program, intending to repurchase $2 billion in 2025.

Royalty Pharma plc will acquire its external manager, RP Management, LLC, and implement a $3 billion share repurchase program, aiming to enhance shareholder value through cost savings and increased returns.

Royalty Pharma anticipates full-year 2024 Portfolio Receipts of approximately $2.8 billion, at the upper end of its guidance, and highlights a robust development pipeline.

Royalty Pharma plc has entered into an amended Exchange Agreement and restated the articles of association of RP Holdings in connection with a restructuring of RPI EPA Holdings, LP.

Royalty Pharma announced a 15% increase in Portfolio Receipts for the third quarter of 2024 and raised its full-year guidance.

Royalty Pharma will receive a $25 million milestone payment due to the FDA approval of KarXT, a drug for the treatment of schizophrenia.

Royalty Pharma reported a 12% increase in Portfolio Receipts for the second quarter of 2024, exceeding expectations and leading to an upward revision of full-year guidance.

Royalty Pharma is set to receive substantial royalties after the FDA approved Voranigo, a new drug for glioma, triggering a $905 million payment to Agios and a royalty agreement.

Royalty Pharma has increased its ownership of royalties from the drug Evrysdi by acquiring a portion of PTC Therapeutics' retained royalties for $242 million upfront.

Royalty Pharma has successfully issued $1.5 billion in senior notes across three tranches with varying maturities and interest rates.

Royalty Pharma's shareholders voted to approve all ten proposals at the company's annual general meeting held on June 6, 2024.